These authors contributed equally to this work. 
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Internal tandem duplication (ITD) mutations in the FLT3 gene on chromosome 13 occur in 25% of patients with acute myeloid leukaemia (AML) and result in impaired overall survival (OS). 1 Patients with a high allelic ratio (AR) of ITD mutant to wild-type FLT3 in genomic DNA have an even poorer prognosis. 2 AR may be a predictor of response to FLT3 inhibitors 3 and may also interact with other mutations in influencing disease risk. 4, 5 AR may be dependent on a number of factors including loss of the wild-type allele. Acquired isodisomy (AID) results in loss of the wild-type allele, through duplication of the mutant allele with segmental loss of the wild-type allele. Although studies 6 have shown the importance of AID at chromosome 13 (AID13) at relapse, the impact of AID13 at diagnosis is unclear. This study aimed to identify the relationship between AID13 and FLT3-ITD AR and investigated the outcomes of patients with AID13. All patients diagnosed with AML who underwent FLT3 mutation analysis in the West Midlands Regional Genetics Laboratory between 2002 and 2015 are included in this study. FLT3 and NPM1 mutation analysis by PCR of genomic DNA was undertaken as described. 7 PCR products were identified using fluorescencebased fragment analysis (Applied Biosystems, Life Technologies, Paisley, UK). Allelic ratio (AR) (mutation: wild-type ratio in genomic DNA) was determined from the relative peak heights. AID was determined by analysis of microsatellite markers along chromosome 13 in patients with AR 40.25 Complete remission, event-free survival (EFS) and OS were defined as described. 9 OS and EFS were estimated by the Kaplan-Meier method. Survival curves were compared using the log-rank test.
Variables were compared using Wilcoxon or χ 2 test as appropriate. Statistical analyses were performed with R 3.0.3, and the R-packages 'survival' (Vienna, Austria) and SPSS (version 19, Armonk, NY, USA). Two hundred and eighty-nine patients diagnosed with FLT3-ITD mutated AML are described (Supplementary Table 1 ). The median age at diagnosis was 61 years. Of 280 patients tested, 45% had the NPM1 exon 12 mutation. Cytogenetic classification by Medical Research Council criteria 10 showed 77% of 267 patients were of intermediate risk.
We investigated which factors influenced AR. The first factor was loss of the wild-type allele. Loss of the wild-type allele can occur through the loss of all or part of chromosome 13 but was seen in only three patients. The most frequent mechanism for loss of the wild-type allele is the presence of AID13; this was seen in 12.8% (n = 34/266) of patients with FLT3-ITD AML at diagnosis. AID13 was associated with a significant increase in AR (Wilcoxon test P o 0.0001, Supplementary Figure 2a) . However, AR is an imperfect surrogate for loss of the wild-type allele as 2 patients with AID13 had an AR o 0.5, and conversely, 106 patients with an AR 40.5 did not have AID13. AID13 itself was associated with an increased white cell count, which was not statistically significant (Wilcoxon test P = 0.096) (Supplementary Figure 2b) . AID13 was significantly associated with an intermediate cytogenetic risk profile and the presence of a NPM1 mutation (χ 2 : P o0.05) (Supplementary Figure 2c) .
AR is also thought to be associated with the size of ITD, and the presence of contaminating normal cells. Therefore, we also investigated the relationship between these factors and AR. There was no association between AR and ITD size. The presence of contaminating cells is inversely correlated with the percentage of blasts in the sample. Although the association between AR and blast percentage was statistically significant, the correlation was very weak (Pearson's correlation coefficient +0.154 (P = 0.02)) ( Supplementary Figures 3a and b) . Having accounted for these other factors, this suggests AID13 is the key factor affecting AR.
Outcomes were analysed for 179 patients treated with curative intent who did not have acute promyelocytic leukaemia. The majority of these patients were treated on the concurrent national AML cooperative trials, with a standard combination of anthracyclines and cytarabine (Supplementary Table 1 ). Patients obtained complete remission independent of AID13 or AR level ( Supplementary Figures 4a and b ). An AR level of 0.5 to split the patient population was based on its use in previous studies.
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Post-remission outcome is strongly influenced by choice of consolidation treatment, in particular allogeneic stem cell transplant (SCT). To understand the influence of AR and AID13 on outcomes and the role of SCT in the management of these patients we stratified time-event analysis based on whether patients received SCT or chemotherapy only.
In patients treated with chemotherapy alone, an AR ⩾ 0.5 was compared with an AR o0.5. A high AR conferred a worse prognosis in both EFS (P = 0.023) and OS (P = 0.039) (Figure 1a) . In the same patients, the presence of AID13 also conferred a worse prognosis in EFS (P = 0.057) and OS (P = 0.029) (Figure 1b) . Because AID13 increases the AR, it is important to understand the relative contribution of AID13 to a high AR. High-AR patients were therefore stratified into those with and without AID13. The poor prognostic impact of AR ⩾ 0.5 was no longer significant when AID13 patients were not included, measured by both EFS (AR ⩾ 0.5 without AID13 vs ARo0.5, P = 0.064) and OS (AR ⩾ 0.5 without AID13 vs ARo 0.5, P = 0.119).
Of the 179 non-acute promyelocytic leukaemia patients treated with curative intent, 70 received a SCT (Supplementary Table 2 ). High AR (⩾0.5) did not have a poor prognostic impact in the SCT-treated patients (EFS: P = 0.477; OS: P = 0.669), Supplementary Figure 5a) . Similarly, AID13 did not confer a poor prognostic impact in patients treated with SCT (EFS: P = 0.663; OS: P = 0.536), Supplementary Figure  5b) . There was no impact from a high AR (⩾0.5) in patients without AID13 treated with SCT, as seen with those treated without SCT (EFS: P = 0.281; OS: P = 0.823, Supplementary Figure 5c) .
Of the 70 SCT-treated patients, 28 (40%) remain alive. Seventeen of the 70 had AID13, and, of these, 6 remain alive.
Eleven died, six from relapse and five from NRM. Seven out of eight patients with AID treated with intensive chemotherapy alone died with active disease. This suggests that SCT may ameliorate the poor risk of AID13.
AID has been a common finding at relapse. 6 Of 45 patients who had sequential relapsed bone marrow samples, 5 developed AID13 as a new finding. Six relapsed with a FLT3-ITD-negative clone, consistent with data that it is a secondary driver mutation. 11 Consistent with AID13 being a driver of relapse, in five out of six patients with AID13 with available relapse data there was no loss of AID13 at relapse.
In summary, we show that AID13 at diagnosis is associated with impaired OS in patients who are treated with chemotherapy alone, and this is the major part of the effect of a high AR. A smaller study 12 also used microsatellite markers to investigate the impact of AID13, and suggested that AID13 resulted in a decreased OS. The frequency of AID13 in our study of consecutive patients (12.8%) was lower than that described by this smaller study (8/ 23 patients, 34% ). The frequency of AID13 at an intermediate mutant level (0.25-0.5) was low in our study (1/60). Another study 13 identified only 2 of 34 patients with AID13 using single-nucleotide polymorphism arrays, confirming this result.
This study has demonstrated the poor prognosis of patients with AID13 or a high AR in patients treated with chemotherapy alone. The poor outcomes were ameliorated in those who received SCT. Our data are consistent with a prospective study from the German Austrian AML Study group who showed that SCT improved OS compared with intensive chemotherapy alone in patients with FLT3-ITD with a high AR, but no benefit was seen in those with a low AR. 2 Several studies have implicated the AR of FLT3-ITD as an important factor in determining the outcomes of patients with this mutation. 1, [3] [4] [5] This study suggests that mitotic recombination leading to AID13 is a major mechanism of increasing the allelic ratio of FLT3-ITD. Importantly, it is detectable by an accessible laboratory assay with a binary outcome-in contrast to allelic ratio, which is a continuous variable. Our data demonstrate differences in the outcomes of patients with AID13, suggesting that patients with heterozygous and homozygous FLT3-ITD mutations are distinct cohorts. This is consistent with murine models where homozygous FLT3-ITD mutation results in a more severe myeloproliferative phenotype than those with either a heterozygous 14 or a hemizygous mutation. 15 The loss of the wild-type allele is also important, as seen in FLT3-ITD hemizygous cells that show a more aggressive phenotype than the heterozygous cells, which retain the wild-type copy of FLT3.
15 AID13 is a single event that results in both gain of a second FLT3-ITD allele and loss of the wild-type allele.
